8-K: Calidi Biotherapeutics Advances CLD-401, Raises $6.5M

Calidi Biotherapeutics reported Q4 and full-year 2025 financial results, highlighting progress in its CLD-401 clinical program and recent capital raises.

Summary

• Net loss attributable to common stockholders for the fourth quarter of 2025 was $4.1 million, or $0.57 per share, consistent with $4.1 million, or $3.23 per share, for the same period in 2024.
• Full-year 2025 net loss attributable to common stockholders increased to $25.6 million, or $5.95 per share, compared to $23.8 million, or $35.70 per share, for the full year 2024.
• Research and development expenses for the full year 2025 were $9.7 million, up from $8.9 million in 2024.
• General and administrative expenses for the full year 2025 decreased to $10.5 million from $12.9 million in 2024.
• Cash and restricted cash totaled approximately $5.8 million as of December 31, 2025, down from $9.8 million as of December 31, 2024.
• The company raised $6.0 million in gross proceeds from an underwritten public offering in Q1 2026 and $0.5 million from At-The-Market (ATM) sales in Q4 2025.
• A partnership was announced with Avance Clinical, an Australian CRO, to accelerate the initiation of a first-in-human clinical trial for CLD-401 in Australia.
• Feedback from the FDA through Type D interactions indicates alignment on manufacturing and analytical approaches for CLD-401, with an Investigational New Drug (IND) filing expected by the end of 2026.
• A partnership was established with Matica Bio for the GMP manufacturing of CLD-401.
• New data on in situ T-cell engagers (TCEs) for solid tumors, derived from the RedTail platform, was presented at the 2026 AACR Immuno-Oncology (AACR-IO) conference.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses persist, the operational progress in advancing CLD-401 towards clinical trials, positive FDA interactions, strategic partnerships, and successful capital raises indicate significant developmental momentum for a pre-revenue biotech.

Positives

• Successfully raised $6.0 million in gross proceeds from a public offering in Q1 2026 and $0.5 million from ATM sales in Q4 2025, strengthening the balance sheet and extending the cash runway.
• Secured a partnership with Avance Clinical to accelerate the initiation of a first-in-human clinical trial for CLD-401 in Australia.
• Received positive feedback from the FDA through Type D interactions, indicating alignment on manufacturing and analytical approaches for CLD-401.
• Established a partnership with Matica Bio for the GMP manufacturing of CLD-401, leveraging their specialized expertise.
• Presented new data on in situ T-cell engagers (TCEs) at the 2026 AACR-IO conference, demonstrating expansion of the RedTail platform's capabilities.
• General and administrative expenses decreased to $10.5 million for the full year 2025 from $12.9 million in 2024.

Negatives

• Full-year net loss attributable to common stockholders increased to $25.6 million in 2025 from $23.8 million in 2024.
• Cash and restricted cash decreased to $5.8 million as of December 31, 2025, from $9.8 million as of December 31, 2024, indicating significant cash burn.
• Research and development expenses increased to $9.7 million for the full year 2025 from $8.9 million in 2024, reflecting ongoing development costs without revenue generation.

Risks

• The risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• The risk that early results of clinical trials do not necessarily predict final results and that one or more clinical outcomes may materially change.
• The risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates.
• Uncertainty regarding the timing, cost, and results of research and development activities and preclinical studies.
• Preliminary interactions with the FDA may not be indicative of future outcomes or regulatory success.
• Potential impact from changes in applicable laws or regulations.
• Challenges related to manufacturing and supply chain matters.
• Changes in business, market, economic, or competitive conditions.

Future Outlook

Calidi Biotherapeutics plans to file an Investigational New Drug (IND) application for CLD-401 with the FDA by the end of 2026 and is focused on rapidly initiating a first-in-human clinical trial for CLD-401 in Australia. The company also intends to continue advancing its pipeline utilizing the RedTail platform, including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Management Comments

• "We are extremely excited about the continued progress at Calidi."
• "We continue to advance CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts."
• "We have also expanded what the RedTail platform can do with our new approach of in situ T-cell engagers."

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics' focus on oncolytic viruses and T-cell engagers aligns with a growing trend in oncology towards targeted immunotherapies. The strategy of initiating clinical trials in Australia to accelerate development is a common tactic for biotech companies seeking faster regulatory pathways and potentially lower costs compared to the U.S. market, while still pursuing FDA approval in parallel. The partnerships for manufacturing and clinical research are crucial for a development-stage company to leverage external expertise and infrastructure.

Related Party Transactions

• Related party accounts payable of $18 thousand as of December 31, 2025.
• Related party accrued expenses and other current liabilities of $530 thousand as of December 31, 2025.
• Related party term notes payable, net of discount, including accrued interest of $2,702 thousand as of December 31, 2024.
• Related party bridge loan payable, including accrued interest of $223 thousand as of December 31, 2024.
• Related party other current liability of $638 thousand as of December 31, 2024.
• Related party warrant liability of $8 thousand as of December 31, 2025.
• Interest expense related party of $76 thousand for the year ended December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for future value creation if clinical trials are successful, but also dilution from recent capital raises and ongoing risk from significant losses.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Customers (future): Potential for new therapeutic options for non-small cell lung cancer, head and neck cancer, and other solid tumors.
• Suppliers/Partners: Continued engagement and revenue for partners like Avance Clinical and Matica Bio.
• Creditors: The company's ability to meet obligations depends on successful capital raises and pipeline progression.

Next Steps

• Rapidly initiating a first-in-human clinical trial for CLD-401 in Australia.
• Filing an Investigational New Drug (IND) application for CLD-401 with the FDA by the end of 2026.
• Continuing to advance CLD-401 towards the clinic.
• Further developing the RedTail platform, including the novel approach to incorporate in situ T-cell engagers in solid tumors.

Key Dates

Recommendation

Calidi Biotherapeutics is a pre-revenue biotechnology company making tangible progress in its clinical development pipeline, particularly with CLD-401. The successful capital raises and strategic partnerships are crucial for extending its cash runway and advancing its lead candidate. However, the company continues to incur significant net losses and burn cash, which is typical for its stage but presents inherent risks. The stock is speculative, and while operational milestones are positive, the long path to commercialization and regulatory approval warrants a 'hold' recommendation for investors monitoring its progress, balancing potential upside with significant execution risks.

Keywords

Calidi Biotherapeutics, CLDI, Biotechnology, Oncolytic Virus, Genetic Medicines, CLD-401, RedTail Platform, T-cell Engagers, Cancer Therapy, Clinical Trials, FDA, IND Filing, GMP Manufacturing, Financial Results, Q4 2025, Full Year 2025